An observational study in Hypochondroplasia, sponsored by BioMarin Pharmaceutical. Recruiting at 43 sites in 11 countries. Open to participants aged Up to 15 Years. Per ClinicalTrials.gov, last updated 2025-04-03.
Sponsored by BioMarin Pharmaceutical · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population will include approximately 400 pediatric individuals with hypochondroplasia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children with Hypochondroplasia
Change in annualized growth velocity (AGV)
Time frame: Every 6 months through end of study, up to 15 years
Change in Height Z-score
Time frame: Every 6 months through end of study, up to 15 years
Change in Height
Time frame: Every 6 months through end of study, up to 15 years
Change in BMI
Time frame: Every 6 months through end of study, up to 15 years
Change in BMI Z-score
Time frame: Every 6 months through end of study, up to 15 years
Change in ratios of upper to lower body segments
Time frame: Every 6 months through end of study, up to 15 years
Change in ratios of upper and lower leg length ratio
Time frame: Every 6 months through end of study, up to 15 years
Change in ratio of arms span to standing height ratio
Time frame: Every 6 months through end of study, up to 15 years
Change in Quality of Life in Short Statured Youth (QoLISSY) physical domain
Time frame: Every 52 weeks through end of study, up to 15 years
Change in Quality of Life in Short Statured Youth (QoLISSY) total score
Time frame: Every 52 weeks through end of study, up to 15 years
Change in patient global impression of severity (PGI-S)
Time frame: Every 52 weeks through end of study, up to 15 years
Change in caregiver global impression of severity (CaGI-S)
Time frame: Every 52 weeks through end of study, up to 15 years
Frequency of event rates of medical events of interest
Time frame: Every 6 months through end of study, up to 15 years
Proportion of children who report use of growth hormone, treatment patterns and impact on growth
Time frame: Every 6 months through end of study, up to 15 years
Proportion of children who report limb lengthening surgery
Time frame: Every 6 months through end of study, up to 15 years
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Dec 2043, 241 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hypochondroplasia